Lentiviral Vector CDMOs with Clean FDA Inspection History

· updated as new inspection, certificate, and trial data enters the platform
19
CDMOs tracked
19
Fully scored
12
With FDA records
62
FDA inspections
99
EMA/MHRA GMP certs

Lentiviral vectors are the workhorse of ex vivo gene therapy — used to engineer T cells for CAR-T, TCR programs, and to modify hematopoietic stem cells for inherited disorders. Because the vector integrates into the genome of patient-bound cells, lentiviral manufacturing carries the regulatory weight of a critical starting material under full GMP, mandatory replication-competent lentivirus (RCL) testing, and BSL-2 containment throughout production.

Selecting a lentiviral vector CDMO comes down to five buyer-critical dimensions: BSL-2 containment maturity and site inspection history on lentivirus specifically, a scalable suspension (or well-run adherent) platform, qualified titer + potency + RCL assays, capacity headroom at your target dose × patient volume, and defensible tech-transfer support. The rankings below score each CDMO on FDA inspection classifications, EMA/MHRA GMP density, ClinicalTrials.gov sponsor breadth, and monitored capacity signals — a composite that reflects the regulatory record and operational depth needed for material that lands in patient-bound cells.

FDA inspection outcomes across these CDMOs: 24 NAI (no action), 38 VAI (voluntary action), 0 OAI (official action). Leading inspection & GMP sites: United States (43), UNITED KINGDOM (38), Denmark (23), Germany (10), United Kingdom (7).

Last updated 2026-11-20. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

Ranked by Signal Score (0–100). Fully evidenced marks a CDMO scored on all four pillars with at least one confirmed clinical program. Partly scored and profile-only CDMOs follow the scored rows. How we score

Showing all operator types.

# CDMO Signal Score Quality FDA · GMP Last FDA inspection Capacity Programs
1
PB
San Diego, CA · Shaoxing, China, Liverpool, UK, Ningbo China
86.9 100.0 5 insp · 1 GMP 2026-08-14 · NAI Available —
2
CR
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
86.3 99.2 9 insp · 11 GMP 2026-05-01 · NAI Limited —
3
RP
Keele, UK · Sodertalje, SE
82.9 100.0 0 insp · 3 GMP None on file — —
4
BR
Glasgow, UK · Rockville, MD
Hiring · 16 open roles
Also makes its own products
80.3 97.2 6 insp · 10 GMP 2026-05-13 · VAI — —
5
AG
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
Hiring · 38 open roles
Fully evidenced
79.9 99.8 4 insp · 27 GMP 2026-05-29 · NAI Available 2 programs
6
SK
Dublin, Ireland. Rancho Cordova, CA. King of Prussia, PA. Houston, TX. Korea. France.
79.5 100.0 — None on file Available —
7
BV
Turku, Finland
Hiring · 2 open roles
79.4 99.8 1 insp · 4 GMP 2024-12-19 · VAI — —
8
GZ
Indianapolis, IN · Lexington, MA
Hiring · 26 open roles
78.1 100.0 1 insp · 0 GMP 2025-08-27 · NAI Available —
9
AA
Rockville, MD · Alachua, FL · Munich, DE
78.1 100.0 0 insp · 1 GMP None on file — —
10
NG
Leiden, NL
78.1 100.0 0 insp · 1 GMP None on file — —
11
ET
Jumet, BE
78.1 100.0 0 insp · 4 GMP None on file — —
12
PG
Berlin, DE
78.1 100.0 0 insp · 4 GMP None on file — —
13
AD
London, United Kingdom
78.1 100.0 0 insp · 2 GMP None on file — —
14
TF
Plainville, MA · Alachua, FL · Cambridge, MA
Hiring · 299 open roles
Fully evidenced
77.6 93.2 19 insp · 10 GMP 2026-06-30 · NAI Available 2 programs
15
AG2
San Carlos, CA
77.6 98.8 1 insp · 0 GMP 2025-04-18 · VAI — —
16
OX
Oxford, United Kingdom
Hiring · 4 open roles
Fully evidenced
Also makes its own products
76.2 100.0 2 insp · 13 GMP 2024-06-17 · NAI Available 7 programs
17
CI
Cincinnati, OH
Hiring · 2 open roles
Fully evidenced
Academic / national centre
75.1 99.6 2 insp · 0 GMP 2025-02-05 · NAI — 1 program
18
NR
San Diego, CA · Boston, MA · RTP, NC · Philadelphia, PA
Hiring · 100+ open roles
Fully evidenced
73.6 95.6 1 insp · 0 GMP 2025-01-21 · VAI Available 9 programs
19
Basel, Switzerland
Hiring · 100+ open roles
Fully evidenced
72.8 86.6 11 insp · 8 GMP 2025-09-29 · VAI — 1 program
How we score CDMOs →

What to evaluate in a Lentiviral Vector CDMO

Containment & biosafety
Lentivirus requires BSL-2 manufacturing with segregated suites and validated decontamination. Confirm the site's containment design and replication-competent lentivirus (RCL) testing strategy.
Process platform maturity
Suspension culture scales more cleanly than adherent for larger batches. Ask whether the platform is serum-free and how it performs at your target dose and patient volume.
Analytics & potency
Titer, infectivity, and potency assays drive lot release. A CDMO with qualified, established assays de-risks comparability and tech transfer.
Regulatory track record
Cross-check FDA 483 history and EMA/MHRA GMP coverage — both are shown in the rankings above and on each profile.

Lentiviral Vector CDMOs — Frequently Asked Questions

Who are the top Lentiviral Vector CDMOs?
Among Lentiviral Vector manufacturers with a fully evidenced Signal Score (all four pillars and at least one ClinicalTrials.gov match), the highest are AGC Biologics, Thermo Fisher Scientific, Oxford Biomedica. The table above is the full list. CDMOs cannot pay to change a score.
How many Lentiviral Vector CDMOs have FDA inspection records?
CDMO Signal tracks 12 Lentiviral Vector CDMOs with FDA inspection records and 99 EMA/MHRA GMP certificates across the group.
What should I look for in a lentiviral vector CDMO?
Prioritize BSL-2 containment, a mature suspension platform, qualified titer/potency/RCL assays, and a clean FDA and EMA/MHRA record. Match capacity to your dose and patient volume, and confirm tech-transfer support.
How is lentiviral vector manufacturing different from AAV?
Lentivirus integrates into the host genome and is produced under BSL-2 with RCL testing, typically for ex vivo cell engineering. AAV is non-integrating, made at higher volumes, and used mainly for in vivo gene therapy.
Related modalities
Cell Therapy CDMOs CAR-T CDMOs AAV / Gene Therapy CDMOs
Other Modalities
AAV CAR-T Cell Therapy mRNA/LNP Plasmid DNA Biologics Oligo/ASO Adenoviral Gene Editing Exosome Recombinant Proteins ADC Gene Therapy Cell & Gene Therapy Viral Vector